23 Stock Top Picks and 7 ETF (Nov 30 Dec 6)

They executed on their service business which continues to grow, and all their watch and so on is growing very nicely. 5G should help them out but not this year. He sold a little because it became a very large percentage of his portfolio. They will continue to buy back their shares. They continue to…

Has done extremely well on both organic growth and on the market's re-rating. Will be beneficiaries as we move more to plastic in the post-pandemic world. Trading at a high 30s multiple, a bit extreme. Fewer opportunities and more risk in the face of Square, PayPal, and the like.

He hasn't added to his position, but for yield players, it is at an attractive level. This is one of his top pick of the week.

(A Top Pick Dec 04/18, Up 2%) Safety play. A place to park cash. Never touches a GIC, because they're not liquid.

An alternative to straightforward S&P500. These focus on about 181 dividend growers. It has all the biggest, solid companies. He has been buying a lot of this one lately. Yield 1.41%

(A Top Pick May 07/20, Up 12%) Strongly outperformed the broad market starting late February. It was a pandemic trade. From late March to early June, it gave it all back. We've seen a baseline, and now it's starting to outperform again. August and September are dangerous times for the market, so this is a…

He is not a big fan of ETFs. MPL ETFs get around foreign tax with-holdings. You are investing in an environment of weak energy prices. If you have some riskier money you might look at this one. He would not tend to buy it for his clients. He thinks it will have some resistance here…

We've seen the bounce from March 23, but they haven't performed well since then. There's lack of visibility on the future. Until we get past Covid, it's not his favourite sector. It has structural headwinds against it. People are out of work, and we haven't had the wave of bankruptcies yet. Better places to look.

(A Top Pick May 07/20, Up 8%) Healthcare sector is a bit exhausted right now, and seeing relative weakness. He's walked back from it a bit. Coming up to an election, healthcare can become a political football.

He prefers CIBC or RY (capital markets are driving stronger revenue), and he isn't looking at BNS. He has little exposure to financial services. However, banks are showing improving technical signals, like attractive valuations and starting to approach previous highs. BNS has exposure to Latin America, which is another headwind.

A spin-off of Brookfield Asset Management. For every 170 shares of BAM-T one owned, they received one share of TSU-T. They underwrite smaller BTB insurance. They can sell-off re-insurance for a recurring fee stream in the US – a process called “fronting”. On paper it looks like they operate at a loss, but it will…

(A Top Pick Dec 04/18, Up 32%) Great tech ETF.

It has a great dividend yield. The risk on all these companies is that their loan loss book gets worse. They deferred a lot of payments on loans. It has a great retail franchise but they grew their investment banking side. He thinks you are fine owning it at these levels.

The premier property casualty company in North America. They are not subject to low interest rates because they reset their prices every year. 10 times earnings and double digit growth for the last decade. It is on sale today. Minimal impact from CoVid19. (Analysts’ price target is $124.25)

They are primarily focused on residential single family homes in the US. They focus more mid-market than their peers. The rents are lower so affordable for tenants today. About 98% occupied. There has been a lot of demand for people leaving high rises for single family homes. (Analysts’ price target is $11.39)

(A Top Pick Dec 05/18, Up 45%) It's a Blackstone-sponsored company that bought a bunch of single-family homes and rent them out. Blackstone IPO'd this and sold it in tranches over time. Now, the stock has legs and doesn't need the parent's support. They rent to tenants and are adding ancillary businesses, like pet services…

The only REIT in health sciences, and is benefiting from demand to treat and cure COVID-19 and other diseases. Though considered an office REIT, she notes that many of its tenants cannot work from home. Rent collection is impressive at 99%, because life sciences are deemed essential. It leased 1 million sq. feet in Q2,…

He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has…

A turnaround story. They have done a good job stabilizing the company. It has a lot of debt and legal issues to resolve. The debt levels are probably still too high. They are spinning out their eyecare business which is their crown jewel. There is some more work to do before taking a position.

An excellent health operator. But if this crisis continues, employment levels may remain very low which could impact UNH. But UNH has probably seen the worst of the pandemic and this is a blue-chip name. Will be fine after this crisis, which she sees passing one day.

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

(A Top Pick Sep 11/19, Up 6%) In his favourite sectors of bio and pharma. Strong in oncology. Diversified pipeline. Trading at a bit of a discount, 15x forward earnings, 2.9% dividend. Compelling story for the dividend and growth in the sector.

(A Top Pick Dec 05/18, Up 31%) They used to make personal care products, but now make healthcare tech products and gaining market share. Managers have executed very well, transforming the company to higher-margin products.

Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.

(A Top Pick Sep 03/19, Down 36%) Last early-march he sold this to raise cash. Their production numbers were way down, but this has bounced back a lot. Problem is, provinces and states are suffering such big deficits, they will spend (a lot) less on buying new buses.

They lead in wireless antennae for cell phones, satellites and sell globally. The pandemic has impacted sales. They had to pause a new plant in Vietnam. The 5G roll-out is back on track. They had to guide down and that pressured the stock. Also have a lot of debt. Overall, though, they will be fine…

Price target: 2,000 Yen An unknown niche Japanese company. Boasts zero debt and pays a near 4% dividend yield. Trades at a very cheap valuation. Creates fine shareholder value.

It is an interesting business. It is specialty pharmacies. They do medication for long term care facilities. They have an interesting pouch technology. They had quite a significant debt load and made a big dent in it when they sold their surgical business. They are trying to pick up new contracts. He has owned it…

Billy Kawasaki’s Insights - Picks from 5i Research. The company has potential to continue to grow at a good rate through acquisitions. Q2 results were satisfactory for investors and their balance sheet remains strong. Unlock Premium - Try 5i Free

It's in the doghouse and it has been an under-performer. The funds have been flowing towards CNQ. We're at the bottom of the cycle, so there are better companies to buy.